Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001127855-12-000525
Filing Date
2012-09-27
Accepted
2012-09-27 11:43:55
Documents
10
Period of Report
2012-05-31

Document Format Files

Seq Description Document Type Size
1 NAPRODIS 10Q, 05.31.12 naprodis10q053112.htm 10-Q 461721
2 NAPRODIS 10Q, CERTIFICATION 302, CEO naprodisexh31_1.htm EX-31.1 10856
3 NAPRODIS 10Q, CERTIFICATION 302, CFO naprodisexh31_2.htm EX-31.2 10959
4 NAPRODIS 10Q, CERTIFICATION 906, CEO/CFO naprodisexh32_1.htm EX-32.1 5441
  Complete submission text file 0001127855-12-000525.txt   2021977

Data Files

Seq Description Document Type Size
5 napr-20120531_cal.xml EX-101.CAL 20387
6 napr-20120531_def.xml EX-101.DEF 41685
7 napr-20120531.xml EX-101.INS 310063
8 napr-20120531_lab.xml EX-101.LAB 75769
9 napr-20120531_pre.xml EX-101.PRE 56770
10 napr-20120531.xsd EX-101.SCH 11019
Mailing Address 13250 GREGG STREET SUITE F POWAY CA 92064
Business Address 13250 GREGG STREET SUITE F POWAY CA 92064 (858) 486-8655
Naprodis, Inc. (Filer) CIK: 0001313938 (see all company filings)

EIN.: 330903494 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 333-122009 | Film No.: 121112356
SIC: 2834 Pharmaceutical Preparations